@entity9769 @entity9770 and XXXX mutations and @entity1561 .

@entity1501 @entity1 @entity9770 @entity1560 @entity9769 @entity1255 @entity96 @entity2186 @entity5784 @entity1561 @entity24038
Common genetic mutations encountered in @entity1501 metabolism may result in increased @entity1255 ( @entity5784 ) levels. It has been reported that increased serum @entity5784 levels may affect the intracellular fat metabolism and may cause enhanced @entity1560 in the liver resulting in @entity1561 ( @entity1561 ). In total, 150 @entity1 diagnosed with FLD by ultrasound examination and 136 healthy control @entity1 that do not have any @entity1560 in the liver were included in the study. @entity1 were grouped as mild (n = 88), moderate (n = 38) or severe (n = 24) according to the @entity96 in ultrasound. Serum liver function tests, @entity5784 , @entity1501 and @entity2186 levels of the @entity1 were studied. The genetic @entity9769 @entity9770 and @entity24038 polymorphisms of the @entity1 were also evaluated. Although there was no significant difference in @entity2186 and @entity1501 levels, in the severe group, @entity5784 levels were significantly higher than that of control and mild groups (p<0.001). By contrast, there was no significant difference in heterozygote @entity9769 @entity9770 and @entity24038 mutations, both @entity9769 @entity9770 and @entity9769 @entity24038 mutations were more common in @entity1561 groups compared with the control @entity1 (p<0.001). We have determined increased @entity5784 levels and increased prevalence of homozygote @entity9769 @entity9770 and @entity9769 @entity24038 mutations in @entity1 with @entity1561 compared with healthy controls. Larger studies are warranted to clarify the etiological role of the @entity9769 mutations and @entity5784 levels in FLD.
